Pyruvate Dehydrogenase as a Therapeutic Target for Nonalcoholic Fatty Liver Disease.
Journal
ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411
Informations de publication
Date de publication:
09 Apr 2021
09 Apr 2021
Historique:
received:
06
12
2020
entrez:
16
4
2021
pubmed:
17
4
2021
medline:
17
4
2021
Statut:
epublish
Résumé
Excess caloric intake combined with a sedentary lifestyle in the general population has greatly increased the prevalence of obesity and nonalcoholic fatty liver disease (NAFLD), which is defined as the accumulation of excess fat in the liver in the absence of alcohol abuse or other attributable causes such as infection with hepatitis C. Furthermore, NAFLD increases the risk for insulin resistance, type 2 diabetes (T2D), and cardiovascular disease, while currently having no approved therapy to counteract its pathology. Thus, increasing efforts to understand the mechanisms responsible for NAFLD have been pursued in preclinical studies, in the hopes of developing novel therapies that can prevent the progression of insulin resistance and/or T2D. The pathology of NAFLD is multifactorial, with proposed mechanisms including inflammation, oxidative stress, and mitochondrial dysfunction to name a few. The latter remains a subject of ongoing debate, but may be attributed to impaired hepatic fatty acid oxidation, thereby increasing the accumulation of triacylglycerol within hepatocytes. More recent studies have also demonstrated that the mitochondrial dysfunction in NAFLD may also encompass impairments in glucose oxidation, despite oxidative energy production having minimal contribution to overall glucose/pyruvate metabolism in the liver. Accordingly, strategies to reverse this defect in glucose oxidation can ameliorate hepatic steatosis and improve glucose homeostasis. We will review herein the evidence supporting impaired hepatic glucose oxidation as a mechanism of NAFLD, while discussing the validity of pyruvate dehydrogenase (PDH), the rate-limiting enzyme of glucose oxidation, as a potential target for NAFLD. In addition, we will discuss potential mechanisms of action by which increased hepatic PDH activity and subsequent glucose oxidation can reverse the pathology of obesity-induced NAFLD, as well as opportunities to target this pathway with clinical agents.
Identifiants
pubmed: 33860188
doi: 10.1021/acsptsci.0c00208
pmc: PMC8033600
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
582-588Informations de copyright
© 2021 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Physiol Rev. 2018 Oct 1;98(4):2133-2223
pubmed: 30067154
Diabetes. 2016 Oct;65(10):2876-87
pubmed: 27385159
Cell Metab. 2020 May 5;31(5):909-919.e8
pubmed: 32275862
Pharmacol Ther. 2012 Mar;133(3):311-23
pubmed: 22133843
Endocr Connect. 2019 Oct;8(10):R157-R168
pubmed: 31581129
Diabetes. 2013 Oct;62(10):3404-17
pubmed: 23835326
Biochem Soc Trans. 2006 Apr;34(Pt 2):217-22
pubmed: 16545080
Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11711-6
pubmed: 22753483
J Biol Chem. 2014 Jun 13;289(24):16615-23
pubmed: 24798336
Circulation. 1996 Jan 1;93(1):135-42
pubmed: 8616920
Hepatology. 2020 Nov;72(5):1605-1616
pubmed: 32043613
Diabetologia. 2013 May;56(5):949-64
pubmed: 23443243
Hepatology. 2017 May;65(5):1543-1556
pubmed: 28027586
J Biol Chem. 1992 Feb 25;267(6):3758-63
pubmed: 1740427
Mol Metab. 2018 Jun;12:12-24
pubmed: 29656110
Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E141-5
pubmed: 20009031
Cell Metab. 2015 May 5;21(5):739-46
pubmed: 25955209
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):377-386
pubmed: 31024089
J Appl Physiol (1985). 1996 Aug;81(2):905-10
pubmed: 8872662
Lancet. 1963 Apr 13;1(7285):785-9
pubmed: 13990765
Diabetes Care. 2018 Feb;41(2):372-382
pubmed: 29358469
Nature. 2014 Jun 5;510(7503):84-91
pubmed: 24899308
Physiol Rev. 2009 Jul;89(3):1025-78
pubmed: 19584320
J Biol Chem. 1969 Sep 10;244(17):4617-27
pubmed: 5808508
Diabetes. 2014 Nov;63(11):3626-36
pubmed: 24848064
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Cell Mol Life Sci. 2019 Jan;76(1):99-128
pubmed: 30343320
Cell Metab. 2019 Jun 4;29(6):1291-1305.e8
pubmed: 31006591
Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):19084-9
pubmed: 22065779
Environ Health Perspect. 1998 Aug;106 Suppl 4:989-94
pubmed: 9703483
Am J Physiol Endocrinol Metab. 2016 Jul 1;311(1):E117-27
pubmed: 27166281
JCI Insight. 2019 Jan 10;4(1):
pubmed: 30626749
Gastroenterology. 2010 Sep;139(3):846-56, 856.e1-6
pubmed: 20685204
Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E46-54
pubmed: 18430968
J Biol Chem. 2014 Feb 14;289(7):4432-43
pubmed: 24356970
Circulation. 2018 May 8;137(19):2052-2067
pubmed: 29330215
Cell Metab. 2007 Jul;6(1):69-78
pubmed: 17618857
Cell Metab. 2017 Feb 7;25(2):262-284
pubmed: 28178565
Sci Rep. 2019 Jul 31;9(1):11124
pubmed: 31366982
Physiol Rev. 2007 Apr;87(2):507-20
pubmed: 17429039
Annu Rev Physiol. 2016;78:181-205
pubmed: 26667070
Can J Cardiol. 2021 Jan;37(1):140-150
pubmed: 32640211
Trends Endocrinol Metab. 2017 Aug;28(8):545-560
pubmed: 28647324
Cell. 2012 Mar 2;148(5):852-71
pubmed: 22385956
Cell Metab. 2012 May 2;15(5):764-77
pubmed: 22560225
Free Radic Biol Med. 2017 May;106:302-314
pubmed: 28242228
Lipids. 2010 Nov;45(11):987-95
pubmed: 20835892